Twelve forms of human hepatic cytochrome P450 were expressed in hepatoma cells by means of recombinant vaccinia viruses. The expressed P450s were analyzed for their abilities to activate the potent hepatocarcinogen aflatoxin B1 to metabolites having mutagenic or DNA-binding properties. Five forms, P450s IA2, 11A3, 11B7, 11A3, and 11A4, activated aflatoxin B1 to mutagenic metabolites as assessed by 
Cytochrome P450st are the principal enzymes involved in the metabolic activation of chemical carcinogens. A number of studies have been conducted in rodents that implicate certain P450 forms in the activation of specific classes of carcinogens (2, 3) . Genetic evidence suggests more directly that certain forms of rodent P450s are involved in chemically induced cancer (4) . The role of human P450 forms in cancer and carcinogen activation, however, is less clear. The noteworthy species differences in P450 expression make it unlikely that one can reliably extrapolate rodent carcinogen activation data to humans (5, 6) . For this purpose, direct analysis of human P450 activation of procarcinogens is essential.
In recent years, a limited number of forms of P450 have been purified from human hepatic tissue (7) . In some instances, these purified enzymes have been directly analyzed for catalytic activities toward various substrates by reconstituting the microsomal environment in vitro with additions of artificial lipid and NADPH-P450 oxidoreductase. However, at least one form of human P450, designated P45ONF,*
is not significantly active when reconstituted in vitro (11) . (12, 13) . However, interpretation of results obtained with the use of purified enzymes and antibodies (12, 13) is limited by the lack of certainty that a particular P450 protein preparation is homogeneous and an antibody is immunospecific. For example, there are four P450s displaying high amino acid sequence similarities and at least two of these proteins comigrate in SDS-containing polyacrylamide gels (14) . The use of vaccinia virus-mediated cDNA expression (14) offers a new way to evaluate the catalytic activities of human P450s and circumvents problems inherent with P450 and antibody preparations. By expressing, in cultured cells that are virtually devoid of endogenous P450s, cDNAs encoding the major P450s expressed in human liver, it is possible to accurately define which P450 forms metabolize specific drugs or activate carcinogens. In this report, we studied the ability of 12 human P450s to metabolically activate the potent hepatocarcinogen aflatoxin B1 (15) . We determined that at least 5 distinct human P450s are capable of activating aflatoxin B1 to mutagenic and DNA-binding metabolites. In addition, we found that antibodies generated against rodent P450s, immunorelated to 4 of these human P450s, were able to partially immunoinhibit aflatoxin B1 activation catalyzed by extracts of two human liver specimens. Our results establish that not just one form (P45ONF; ref. 13 ) but rather multiple forms of human P450 are capable of activating aflatoxin B1.
MATERIALS AND METHODS
The construction and characterization of recombinant vaccinia viruses containing the cDNAs encoding the P450 proteins IA2 (16), IIA3 (17) , IIB7 (18) , IIC8 (19) , IIC9 (19) , IIF1 (20) , IIIA4 (14) , IIIA5 (14) , and IVB1 (21) 
IVB1.
Hep G2 cells were infected with recombinant vaccinia at a multiplicity of infection of 5. Twenty-four hours after infectThe nomenclature used in this report is that described recently (1). tP450NF was purified from human liver and has an amino-terminal sequence that is compatible with either the HIIA4 (8, 9) or IIIA3 (10) cDNA-deduced amino acid sequences. These proteins display 98% sequence identity and therefore antibody generated against P45ONF would most likely crossreact with both P450 forms.
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tion the cells were harvested, washed with phosphatebuffered saline, and lysed by brief sonication. Mutagenesis assays were performed as described (24, 25) , with each assay mixture containing 3 mg of total lysate protein from vacciniainfected cells. To analyze aflatoxin B1 binding to DNA, =6 x 106 cells were infected with recombinant vaccinia virus and [3H]aflatoxin B1 (15 Ci/mmol, Moravek Biochemicals, San Francisco, CA; 1 Ci = 37 GBq) was added to 13 ml of culture medium in a 10-cm-diameter dish. Cells were harvested 24 hr after infection and were treated with proteinase K (BRL; 500 pug/ml) in 50 mM Tris/HCl, pH 8.0/5 mM EDTA/0.5% SDS for 3 hr at 370C. Protein was removed by repeated phenol extractions and the nucleic acid was dialyzed exhaustively against 10 mM Tris/HCl, pH 8.0/1 mM EDTA. The samples were digested with RNase T1 (10 units/ml) and RNase A (0.1 mg/ml) for 3 hr at 370C, extracted with phenol, and again exhaustively dialyzed against 10mM Tris/HCl, pH 8.0/1 mM EDTA. DNA concentrations were determined by monitoring absorbance at 260 nm (1 A260 = 50 pg/ml). Radioactivity was measured using a liquid scintillation counter. The recovery of DNA was from 220-310 ,ug per 6 x 106 cells.
Immunoinhibition experiments utilized a cell extract fraction prepared from two human liver specimens (Ml and M2, ref. 17) by centrifugation. Frozen liver pieces (5-10 gm) were thawed in phosphate-buffered saline at 4°C and were homogenized (10 strokes with a glass/Teflon tissue disrupter). The homogenate was centrifuged at 10,000 x g for 10 min and the supernatant (S-9) was used as an activation system for the Ames test using 2 ,ug of aflatoxin B1 per plate. Rat P450d (26), P450e (26), P450 IIA2 (27) , and P450 PCN2 (28) were purified as described and were used to elicit antibodies in rabbits. IgG fractions were purified by protein A-Sepharose chromatography.
RESULTS
Metabolic Activation of Aflatoxin B1 by Human cDNAExpressed P450s. The ability of individual human P450s to activate aflatoxin B1 to mutagenic metabolites was measured by the Ames test with use of extracts of total protein from recombinant vaccinia virus-infected cells as an activation system. Five expressed P450s metabolically activated aflatoxin B1 to mutagenic metabolites (Fig. 1) . IIA3, IIIA3, and IIIA4 showed the highest activity, followed by IA2 and IIB7. IIIA5 displayed only weak activation ability. All other P450s (IIC8, IIC9, 1ID6, IIE1, IIF1, and IVB1) were inactive, all producing the same levels of His revertants as were found in cells infected with wild-type vaccinia virus. Human liver S-9 fraction from liver Ml (see Fig. 2 ) was active when concentrations of aflatoxin B1 were low but toxic when concentrations were high (10 ,ug/ml) (Fig. 1) . In contrast, the activations by vaccinia-expressed enzymes appeared to be unsaturable in this assay. S-9, immunoinhibition studies were carried out. Polyclonal antibodies prepared against rat P450s were screened for their abilities to inhibit reactions catalyzed by vaccinia virusexpressed human P450 (unpublished results). Antibody against rat IIB2 was able to inhibit 7-ethoxycoumarin 0-deethylase activity catalyzed by vaccinia-expressed IIB7; antibody against rat IA2 inhibited 7-ethoxycoumarin 0-deethylase activity catalyzed by vaccinia virus-expressed human IA2; antibody against rat IIA2 inhibited coumarin 7-hydroxylase activity catalyzed by human IIA3; antibody against rat IIIAM inhibited IIIA3-, IIIA4-and IIIA5-catalyzed testosterone 6f3-hydroxylase activity. All activities were inhibited more than 98%. These antibodies were then tested to determine the extent of inhibition of aflatoxin B1 activation catalyzed by two human liver S-9 samples. Three antibodies were able to significantly inhibit the S-9-catalyzed production (10 , uCi) was added directly to the medium (15 ml) and cells were incubated for 24 hr. Cells were then harvested, and DNA was purified and its specific radioactivity was determined by liquid scintillation. Results are means ± SD for three experiments. and M2 (B) and used as a source to activate aflatoxin B1 in the Ames assay. Purified IgG prepared from sera of rabbits that had been immunized with rat P450s IIB2 (IIB), IA2 (IA2), IIA3 (IIA), and IIIAl (IIIA) were preincubated with the S-9 fraction for 30 min at 4TC before the Ames assay was performed. Since it is still unclear how many P450s members exist in human subfamilies IIA, IIB, and I1IA, we have not labeled these immunoinhibition curves with notations for specific P450 forms (e.g., IIB7) except for IA2, since this is the only member of the IA subfamily known to be expressed in these two liver specimens. IgG from preimmune rabbits yielded no inhibition, similar to that of IIB.
of His revertants to different extents in both liver specimens (Fig. 2) . Antibody against IA2 inhibited 30o and 40% and antibody against rat IIA2 inhibited 10%o and 30% of aflatoxin B1 activation by samples from livers Ml and M2, respectively. Antibody against rat IIIA1, which would be expected to inhibit all three human IIIA P450s, was the most effective, inhibiting 60% and 65% of aflatoxin B1 activation by S-9 of livers Ml and M2, respectively (Fig. 2) . Only antibody against rat IIB2 was ineffective. This was probably due to the low level or lack of expression of IIB7 in these livers (17 activation was also confirmed by immunoinhibition studies in which antibodies that react with four of the five active human P450s inhibited human liver S-9-catalyzed aflatoxin B1 activation. Only antibody that was raised against rat IIB2, that binds to human IIB7, failed to inhibit the S-9-catalyzed activation. This may have been due to a lack of significant expression of IIB P450s in the two liver samples we analyzed. P450NF2 was reported to be the major P450 form activating aflatoxins in human liver (13) . Our studies, using 12 cloned human P450 cDNAs, showed that five P450s, including IIIA4 and IIIA5, catalyzed aflatoxin B1 activation. Since multiple forms are capable of activating this hepatocarcinogen, it seems unwise to attempt to monitor only P45ONF (or IIIA3/ IIIA4) expression as an indicator of human aflatoxin activation as previously suggested (13) . Since P450s in the IIIA subfamily are expressed to different extents in different livers (13, 14) , it is likely that in livers where either IIIA3 and IIIA4 are predominant, they would be the major enzymes contributing to aflatoxin activation. However, in livers in which the latter P450s are expressed at low levels, other P450 forms such as IA2, IIA3, and IIB7 would play major roles. Based on the results reported here, we conclude that humans have a large capacity to activate this carcinogen. These results reflect one of the notable unique characteristics of carcinogen-metabolizing enzymes and P450s, their overlapping substrate specificities.
Expression of multiple human P450s by use of vaccinia virus or another cDNA expression system should prove extremely valuable in defining the catalytic specificities of individual P450 forms. The roles of these forms in overall hepatic metabolism can be further evaluated by immunological approaches. These studies should prove valuable as a means to develop tests to define human metabolic phenotypes, to design studies in molecular epidemiology to examine the role of P450s in cancer susceptibility, and to develop human P450-based testing systems for chemicals of carcinogenic potential.
Finally, while this manuscript was under review, a report appeared in which the kinetics of production of aflatoxin B1 8,9-epoxide was examined in human hepatic microsomes (29) . The rates of generation of this active metabolite were dose-dependent, with the fraction of metabolites represented by the 8,9-epoxide increasing with decreasing dose of aflatoxin B1. These data suggest that one or more P450 forms with high affinity for this carcinogen may be efficient at generating the active metabolite. These findings are especially significant since the aflatoxin B1 exposure through the human diet is quite low. It should be interesting to determine which forms of human P450 have low Km values and are proficient at production of aflatoxin B1 8,9-epoxide.
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